The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients

Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA, 2008, 300: 2277–2285.PubMedCrossRefGoogle Scholar

Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 2007, 99: 1232–1239.PubMedCrossRefGoogle Scholar

Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg, 2009, 62: 707–709.PubMedCrossRefGoogle Scholar

Tsai C, Griesinger F, Laskin J, et al. Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study. Eur J Cancer, 2009, 7(2 Suppl): 557–558.Google Scholar

Leighl NB, Bennouna J, Yi J, et al. Bleeding events in bevacizumabtreated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer, 2011, 104: 413–418.PubMedCrossRefGoogle Scholar

Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol, 2009, 10: 559–568.PubMedCrossRefGoogle Scholar

Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis, 2007, 49: 186–193.PubMedCrossRefGoogle Scholar

Xia LP, Guo GF, Qiu HJ, et al. Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. Chinese-German J Clin Oncol, 2009, 8: 526–530.CrossRefGoogle Scholar

Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366: 1527–1537.PubMedCrossRefGoogle Scholar

Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol, 2006, 1: 520–525.PubMedCrossRefGoogle Scholar

Haller D, Cassidy J, Clarke S, et al. Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol, 2006, 24(June 20 Suppl): 16S. Abstract 3514.Google Scholar

Micieli JA, Micieli A, Smith AF. Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can J Ophthalmol, 2010, 45: 231–238.PubMedCrossRefGoogle Scholar

Li SM, Zhang R, Li HJ, et al. The clinical observation of 18 patients with recurrent ovarian carcinoma treated with bevacizumab combined with chemotherapy. Chin J Clinicians (Electr Edit) (Chinese), 2010, 4: 322–325.Google Scholar

Li BJ, Wu XF, Zhu RX. Lobaplatin tegafur combined with bevacizumab in treatment of advanced colorectal cancer — a clinical research. J Huaihai Med (Chinese), 2010, 28: 315–316.Google Scholar

Wu XN, Zhao YB, Wu JY, et al. Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer. Acta Acad Med Sin (Chinese), 2010, 32: 417–420.Google Scholar

Xie JM, Xie YL, Chen JZ, et al. Effect of bevacizumab combined with FOLFOX4 on advanced colorectal cancer. Chin Trop Med (Chinese), 2010, 10: 1393–1394.Google Scholar

Shi YY, Wang FL. Clinical curative effect of bevacizumab combined PB project to treat cervical carcinoma in middle and late stage. Chin Healthcare Front (Chinese), 2009, 4: 104–105.Google Scholar

Wu W, Xu LY, Liu Z, et al. Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer. Chin J Lung Cancer (Chinese), 2009, 12: 231–235.Google Scholar

Lin JG, Luo Y, Shi ZH, et al. Twenty-eight cases report of bevacizuamb combined with mFOLFOX6 in treatment of advanced carcinoma of stomach. Chin J Cancer Prev Treat (Chinese), 2008, 15: 546–547.Google Scholar

Zhao L, Zhou JF, Guan M, et al. Five cases with advanced colorectal cancer treated with combination of bevacizumab and chemotherapy. Chin Clin Oncol (Chinese), 2007, 12: 385–387.Google Scholar

Li HM, Lu HJ, Feng R, et al. The short-term efficacy of 20 patients with metastatic colorectal cancer treated with bevacizumab. Shangdong Med (Chinese), 2007, 47: 54–55.Google Scholar

Chen LX, Zhou Q, Chen YB, et al. Clinical observation of advanced tumor patients treated by avastin combined with chemotherapy. J Basic Clin Oncol (Chinese), 2007, 20: 495–497.Google Scholar

Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 2008, 26: 2013–2019.PubMedCrossRefGoogle Scholar

Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 2004, 350: 2335–2342.PubMedCrossRefGoogle Scholar

Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 2007, 25: 1539–1544.PubMedCrossRefGoogle Scholar

Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 2009, 20: 1842–1847.PubMedCrossRefGoogle Scholar

Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol, 2008, 26: 5326–5334.PubMedCrossRefGoogle Scholar

Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol, 2004, 22(July 15 Suppl): Abstr 3528.Google Scholar

Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-smallcell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol, 2010, 11: 733–740.PubMedCrossRefGoogle Scholar

Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355: 2542–2550.PubMedCrossRefGoogle Scholar

Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2004, 22: 2184–2191.PubMedCrossRefGoogle Scholar

Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer, 2008, 9: 102–105.PubMedCrossRefGoogle Scholar

Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res, 2010, 16: 269–278.PubMedCrossRefGoogle Scholar